About 88,300 results
Open links in new tab
Amgen's Rocatinlimab Has Commercial Potential Despite …
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis …
Amgen reports success for eczema and myasthenia gravis …
Amgen stock slips 3% following Phase 3 data for rocatinlimab, …
HORIZON: Rocatinlimab Effective in Adults With Atopic Dermatitis
Amgen claims success for two immune drugs, but results …
Collaborating to Address Moderate to Severe Atopic Dermatitis - Amgen
Amgen Stock: Pipeline Updates, Uplizna Performs And Rocatinlimab …
- Some results have been removed